Company Update (NASDAQ:INCY): Incyte Corporation Clinical Portfolio to be Featured in 23 Abstract Presentations at the 2015 ASCO and EHA Annual Meetings


Incyte Corporation (NASDAQ:INCY) announced that 23 abstracts detailing studies from its clinical development pipeline, including those conducted by Incyte, Novartis and independent investigators, will be presented at the 2015 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings. These conferences will take place from May 29th – June 2nd (ASCO) in Chicago, IL and June 11th – 14th (EHA) inVienna, Austria.

“The abstracts to be presented at ASCO and EHA showcase the depth and breadth of our development pipeline in oncology, as well as the success of our collaboration with Novartis,” stated Rich Levy, MD, Incyte’s Chief Drug Development Officer. “Incyte is committed to translating R&D excellence into new medicines which can improve patients’ lives, and these data, including novel:novel combinations from within our portfolio, provide further evidence of our ongoing progress.”

Highlighted ASCO Abstracts

B-cell malignancies

Phillips, TJ et al; Interim analysis of a Phase 1 study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients with relapsed or refractory B-cell malignancies. Sunday, May 31, 8:00-11:30, discussion 16:30-17:45, abstract # 8520

Forero-Torres, A et al; A Phase 1 study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients with relapsed or refractory classical Hodgkin lymphoma. Sunday, May 31, 08:00-11:30, abstract # 8558

Polycythemia vera

Verstovsek, S et al; Ruxolitinib in polycythemia vera: Follow-up from the RESPONSE trial. Sunday, May 31, 08:00-11:30, abstract # 7087

Chronic myelomonocytic leukemia

Padron, E et al; A multi-institution Phase I trial of ruxolitinib in chronic myelomonocytic leukemia. Sunday, May 31, 8:00-11:30, discussion 11:30-12:45, abstract # 7021

Highlighted EHA Abstracts

B-cell malignancies

Phillips, TJ et al; A Phase 1 study of patients with relapsed or refractory B-cell malignancies treated with a PI3Kδ inhibitor (INCB040093) alone or in combination with a selective JAK1 inhibitor (INCB039110). Friday, June 12; 17:15-18:45, abstract # P326

Forero-Torres, A et al; A Phase 1 study of patients with relapsed or refractory classical Hodgkin lymphoma treated with a PI3Kδ inhibitor (INCB040093) alone or in combination with a selective JAK1 inhibitor (INCB039110). Friday, June 12; 17:15-18:45, abstract # P333

Polycythemia vera

Kiladjian, J-J et al; Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Saturday, June 13; 11:45-12:00, abstract # S447

Verstovsek, S et al; Safety of ruxolitinib in patients with polycythemia vera: Results from the clinical trial program. Saturday, June 13; 17:15-18:45, abstract # P672

Verstovsek, S et al; Effect of Ruxolitinib on Markers of Iron Deficiency: An Analysis of the RESPONSE Trial. Saturday, June 13; 17:15-18:45, abstract # P673

Griesshammer, M et al; Ruxolitinib provides consistent hematocrit control in patients with polycythemia vera resistant to or intolerant of hydroxyurea. Saturday, June 13; 17:15-18:45, abstract # P670

Passamonti, F et al; Ruxolitinib vs best available therapy in patients with polycythemia vera treated in the RESPONSE study: A subgroup analysis of hydroxyurea- and non-hydroxyurea-treated patients. Friday, June 12, 09:30 to Saturday, June 13, 18:45, abstract # E1334

Harrison, CN et al; Complete hematologic control with ruxolitinib in patients with polycythemia vera resistant to or intolerant of hydroxyurea. Friday, June 12, 09:30 toSaturday, June 13, 18:45, abstract # E1353

Myelofibrosis

Daver, N et al; Ruxolitinib in combination with 5-azacytidine as therapy for patients with myelofibrosis. Saturday, June 13; 12:00-12:15, abstract # S448

Deininger, M et al; Ruxolitinib reduces JAK2617F allele burden in patients with myelofibrosis. Saturday, June 13; 17:15-18:45, abstract # P674

Pilar Giraldo, P et al; Safety and efficacy of ruxolitinib in patients with intermediate-1-risk myelofibrosis from an open-label, multicenter, single-arm expanded access study.Saturday, June 13; 17:15-18:45, abstract # P675 (Original Source)

Shares of Incyte closed yesterday at $107.29 . INCY has a 1-year high of $111.93 and a 1-year low of $43.86. The stock’s 50-day moving average is $102.51 and its 200-day moving average is $85.53.

On the ratings front, Incyte has been the subject of a number of recent research reports. In a report issued on May 22, J.P. Morgan analyst Cory Kasimov reiterated a Buy rating on INCY, with a price target of $111, which represents a slight upside potential from current levels. Separately, on April 30, Piper Jaffray’s Joshua Schimmer maintained a Buy rating on the stock and has a price target of $121.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Cory Kasimov and Joshua Schimmer have a total average return of 12.7% and 13.7% respectively. Kasimov has a success rate of 61.3% and is ranked #277 out of 3607 analysts, while Schimmer has a success rate of 64.0% and is ranked #209.

Incyte Corpis a biopharmaceutical company. It discovers, develops and commercializes proprietary small molecule drugs to treat serious unmet medical needs, mainlyin oncology.